Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of oral BAY 63-2521 in symptomatic pulmonary arterial hypertension
CTR20132895Phase 3Completed
- Sponsor
- Bayer
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Jul 2014; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20132895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132895.